封面
市场调查报告书
商品编码
1692206

严重联合免疫缺陷诊断市场 - 全球产业规模、份额、趋势(按疾病类型、按检测类型(TREC、全血球计数、基因检测、生化检测等)、按最终用户、按地区和竞争划分),2020-2030F

Severe Combined Immunodeficiency Diagnosis Market - Global Industry Size, Share, Trends Segmented By Disease Type, By Test Type (TREC, Complete blood count, Genetic Test, Biochemical Test, others), By End User, By Region & Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球严重复合型免疫缺陷 (SCID) 诊断市场价值为 1.826 亿美元,预计在预测期内将出现令人印象深刻的成长,到 2030 年的复合年增长率为 9.20%。严重复合型免疫缺陷 (SCID) 是一种罕见且严重的遗传性疾病,会影响免疫系统,使个体极易受到感染。 SCID 通常被称为泡沫男孩病,因为患有这种疾病的人过去常常生活在无菌环境中以避免接触病原体。 SCID 导致细胞免疫和体液免疫的严重缺陷。这意味着受影响的个体的 T 细胞功能(细胞免疫)严重受损,并且通常缺乏负责产生抗体(体液免疫)的功能性 B 细胞。由于关键免疫细胞缺失或功能障碍,严重复合型免疫缺陷症 (SCID) 患者极易受到多种感染,包括细菌、病毒、真菌和寄生虫感染。这些感染可能反覆发生,严重甚至危及生命。严重复合型免疫缺陷症 (SCID) 的症状通常在生命的最初几个月内出现,因为母体抗体会逐渐减弱。患有严重复合型免疫缺陷症 (SCID) 的婴儿可能会出现持续性的严重感染,且对治疗反应不佳。

市场概况
预测期 2026-2030
2024 年市场规模 1.826亿美元
2030 年市场规模 3.0719亿美元
2025-2030 年复合年增长率 9.20%
成长最快的领域 医院
最大的市场 北美洲

主要市场驱动因素

严重复合型免疫缺陷症(SCID)发生率上升

主要市场挑战

遗传异质性

主要市场趋势

患者倡导和意识

目录

第 1 章:产品概述

第 2 章:研究方法

第 3 章:执行摘要

第 4 章:顾客之声

第 5 章:全球严重复合型免疫缺陷 (SCID) 诊断市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依疾病类型(X 连锁严重复合型免疫缺陷症 (SCID)、ADA-SCID、其他)
    • 按测试类型(TREC、全血球计数 (CBC)、基因测试、生化测试等)
    • 按最终用户(医院、诊断和研究实验室等)
    • 按地区
    • 按公司分类(2024)
  • 市场地图

第 6 章:亚太地区严重复合免疫缺陷 (SCID) 诊断市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 印度
    • 澳洲
    • 日本
    • 韩国

第 7 章:欧洲严重复合型免疫缺陷 (SCID) 诊断市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章:北美严重复合免疫缺陷 (SCID) 诊断市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 墨西哥
    • 加拿大

第 9 章:南美洲严重复合免疫缺陷 (SCID) 诊断市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章:中东和非洲严重联合免疫缺陷 (SCID) 诊断市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 最新动态
  • 产品发布
  • 合併与收购

第 13 章:全球严重复合型免疫缺陷 (SCID) 诊断市场:SWOT 分析

第 14 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章: 大环境分析

第 16 章:竞争格局

  • ARCHIMED SAS
  • PerkinElmer LAS Inc.
  • Health Research, Inc
  • Winfertility, Inc.
  • Portea Medical
  • LaCAR MDX Technologies
  • Labsystems Diagnostics Oy
  • Devyser Diagnostics AB
  • Leadiant Biosciences Inc.
  • Revcovi

第 17 章:策略建议

第18章调查会社について・免责事项

简介目录
Product Code: 18759

Global Severe Combined Immunodeficiency (SCID) Diagnosis Market was valued at USD 182.60 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 9.20% through 2030. Severe Combined Immunodeficiency (SCID) is a rare and severe genetic disorder that affects the immune system, leaving individuals highly susceptible to infections. SCID is often referred to as the bubble boy disease, as individuals with this condition used to live in sterile environments to avoid exposure to pathogens. SCID results in a profound deficiency in both cellular and humoral immunity. This means that affected individuals have severely impaired T cell function (cellular immunity) and often lack functional B cells, which are responsible for producing antibodies (humoral immunity). Due to the absence or dysfunction of critical immune cells, individuals with SCID are extremely vulnerable to a wide range of infections, including bacterial, viral, fungal, and parasitic infections. These infections can be recurrent, severe, and life-threatening. Symptoms of SCID often appear in the first few months of life, as maternal antibodies wane. Infants with SCID may experience persistent, severe infections that do not respond well to treatment.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 182.60 Million
Market Size 2030USD 307.19 Million
CAGR 2025-20309.20%
Fastest Growing SegmentHospitals
Largest MarketNorth America

Key Market Drivers

Rising Incidence of SCID

Efforts to increase awareness and education among healthcare professionals and the public have led to more cases of SCID being identified and diagnosed. For instance, When federal health officials added severe combined immunodeficiency (SCID) to the Recommended Uniform Screening Panel (RUSP), a national guideline for newborn screening (NBS), in 2010, it remained unclear to what degree NBS would improve outcomes for babies diagnosed with SCID. Thirteen years later, a paper by the Primary Immune Deficiency Treatment Consortium (PIDTC) reveals that SCID identified through NBS increases overall survival for babies born with the condition. Babies with SCID lack a functioning immune system, making them vulnerable to fatal infections unless they are treated in infancy with a bone marrow transplant (BMT), also known as hematopoietic stem cell transplantation (HSCT), or clinical trial gene therapy. The new study from PIDTC is a retrospective analysis examining how various factors affected the survival of patients diagnosed with SCID across almost four decades. The paper focuses in particular on how the institution of population-based NBS impacted survival. In a study of 902 patients treated with BMT at 34 PIDTC centers, researchers examined data from several time periods beginning in 1982. They found that for the first three time periods, covering 28 years total, the five-year survival rate of SCID patients treated with BMT hovered at 72-73%. However, in the period from 2010-2018, corresponding to when states instituted NBS for SCID, five-year survival rose to 87%.

Key Market Challenges

Genetic Heterogeneity

SCID is not a single disorder but a group of rare genetic conditions, each caused by specific mutations in different genes. These mutations can affect various aspects of immune system development and function. As a result, there is a wide range of genetic mutations associated with SCID. Due to genetic heterogeneity, SCID is classified into multiple subtypes, each with distinct genetic causes. Common SCID subtypes include X-linked SCID, ADA-SCID, IL7R-SCID, and more. Accurate diagnosis requires identifying the specific genetic mutation responsible for the individual's condition. Diagnosing SCID involves a complex diagnostic process that includes clinical evaluation, immunological assays, and genetic testing. Genetic testing is often required to confirm the diagnosis and subtype, but selecting the appropriate genetic tests can be challenging due to the diversity of SCID-related genes. New, previously unidentified genetic mutations associated with SCID continue to be discovered through research. Identifying novel mutations adds complexity to diagnostic testing, as genetic tests must be updated to include these new variants. Some genetic tests for SCID may not cover the full spectrum of known SCID-related genes or mutations. This can result in a diagnostic gap, as certain mutations may be missed in standard testing panels. Genetic heterogeneity can lead to variability in the clinical presentation and severity of SCID. Two individuals with the same genetic subtype of SCID may exhibit different symptoms and clinical courses. This variability can complicate diagnosis and treatment planning. Genetic counseling is essential for families affected by SCID. The presence of various genetic mutations and subtypes can make genetic counseling complex, requiring a comprehensive understanding of the genetic basis of the condition.

Key Market Trends

Patient Advocacy and Awareness

Patient advocacy groups and organizations dedicated to SCID, such as the Immune Deficiency Foundation (IDF) and the SCID Angels for Life Foundation, play a crucial role in advocating for individuals and families affected by SCID. They provide support, resources, and a platform for raising awareness. Patient advocacy groups often work with policymakers to advocate for improved access to diagnostic testing, treatment, and research funding for SCID. They play a role in shaping healthcare policies related to rare diseases like SCID. Patient advocacy efforts can lead to increased research funding for SCID, driving advancements in diagnostic methods, treatments, and the understanding of the condition. Advocacy efforts have contributed to the inclusion of SCID in newborn screening programs in several regions. This has dramatically increased awareness about the importance of early diagnosis. Awareness campaigns target healthcare providers, including pediatricians and neonatologists, to ensure they recognize the signs and symptoms of SCID and refer infants for diagnostic testing. Public awareness campaigns, often initiated by patient advocacy groups, aim to educate the general population about SCID. These campaigns may include social media outreach, educational materials, and community events. Events like the International SCID Awareness Day, held on October 15th each year, help raise global awareness about the condition. It is an opportunity for patients, families, healthcare providers, and advocates to come together to educate the public. SCID cases that receive media coverage, such as documentaries or news stories, can significantly increase awareness and prompt individuals to seek diagnostic testing if they suspect SCID in their families.

Key Market Players

  • ARCHIMED SAS
  • PerkinElmer LAS Inc
  • Health Research, Inc
  • Winfertility Inc.
  • Portea Medical
  • LaCAR MDX Technologies
  • Labsystems Diagnostics Oy
  • Devyser Diagnostics
  • Revcovi
  • Leadiant Biosciences Inc.

Report Scope:

In this report, the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Severe Combined Immunodeficiency (SCID) Diagnosis Market, By Disease Type:

  • X-linked SCID
  • ADA-SCID
  • others

Severe Combined Immunodeficiency (SCID) Diagnosis Market, By Test Type:

  • TREC
  • Complete blood count (CBC)
  • Genetic Test
  • Biochemical Test
  • Others

Severe Combined Immunodeficiency (SCID) Diagnosis Market, By End-User:

  • Hospitals
  • Diagnostic and Research Laboratories
  • Others

Severe Combined Immunodeficiency (SCID) Diagnosis Market, By region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market.

Available Customizations:

Global Severe Combined Immunodeficiency (SCID) Diagnosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (X-linked SCID, ADA-SCID, others)
    • 5.2.2. By Test Type (TREC, Complete blood count (CBC), Genetic Test, Biochemical Test, others)
    • 5.2.3. By End User (Hospitals, Diagnostic and Research Laboratories, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Test Type
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Test Type
        • 6.3.1.2.3. By End User
    • 6.3.2. India Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Test Type
        • 6.3.2.2.3. By End User
    • 6.3.3. Australia Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Test Type
        • 6.3.3.2.3. By End User
    • 6.3.4. Japan Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Disease Type
        • 6.3.4.2.2. By Test Type
        • 6.3.4.2.3. By End User
    • 6.3.5. South Korea Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Disease Type
        • 6.3.5.2.2. By Test Type
        • 6.3.5.2.3. By End User

7. Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Test Type
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Test Type
        • 7.3.1.2.3. By End User
    • 7.3.2. Germany Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Test Type
        • 7.3.2.2.3. By End User
    • 7.3.3. Spain Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Test Type
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Test Type
        • 7.3.4.2.3. By End User
    • 7.3.5. United Kingdom Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Test Type
        • 7.3.5.2.3. By End User

8. North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Test Type
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Test Type
        • 8.3.1.2.3. By End User
    • 8.3.2. Mexico Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Test Type
        • 8.3.2.2.3. By End User
    • 8.3.3. Canada Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Test Type
        • 8.3.3.2.3. By End User

9. South America Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Test Type
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Test Type
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Test Type
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Test Type
        • 9.3.3.2.3. By End User

10. Middle East and Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Test Type
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Test Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Test Type
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Test Type
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. ARCHIMED SAS
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. PerkinElmer LAS Inc.
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Health Research, Inc
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. Winfertility, Inc.
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. Portea Medical
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. LaCAR MDX Technologies
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Labsystems Diagnostics Oy
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Devyser Diagnostics AB
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Leadiant Biosciences Inc.
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10. Revcovi
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer